Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Acumen Hypotension Prediction Index – EV1000 Clinical Platform
by Edwards Lifesciences
VS
Tempus ECG-AF
by Tempus AI, Inc.

AI Verdict

These tools are adjacent rather than direct competitors, both leveraging AI within cardiology but for distinct purposes. Tool A focuses on real-time prediction and management of acute hypotensive events during surgery or critical care, utilizing continuous hemodynamic monitoring. Conversely, Tool B analyzes 12-lead ECGs to identify long-term risk of new-onset atrial fibrillation in older patients, supporting proactive follow-up.

Choose Acumen Hypotension Prediction Index – EV1000 Clinical Platform if…

Choose Acumen Hypotension Prediction Index if your primary concern is the real-time, proactive management and prevention of acute hypotensive events in surgical or critical care settings. This tool is ideal for clinicians who require continuous hemodynamic monitoring and predictive insights up to 15 minutes in advance to guide timely interventions and optimize patient stability.

View Acumen Hypotension Prediction Index – EV1000 Clinical Platform →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your objective is to identify patients aged 65 or older at an increased risk of developing new-onset atrial fibrillation within the next 12 months, based on routine 12-lead ECG analysis. This solution is best suited for cardiology or primary care practices focused on long-term risk stratification and proactive follow-up to prevent future AF-related complications.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform Tempus ECG-AF
Pricing Unknown Contact vendor
Deployment On-premise (integrated with EV1000 clinical platform and HemoSphere advanced monitoring platform) Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A, Acumen HPI, offers a more direct and interactive user experience by integrating into a real-time monitoring platform with continuous visual feedback, smart alerts, and a dedicated 'Relationship View' screen for immediate clinical insights. In contrast, Tool B, Tempus ECG-AF, operates as a background software solution without a dedicated user interface, integrating via standard protocols to provide results, which suggests a less interactive experience for clinicians.

Clinical Value

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Acumen HPI demonstrates a strong and immediate clinical impact by predicting hypotensive events up to 15 minutes in advance and providing insights into their potential causes, significantly reducing the incidence and duration of hypotension in acute care settings. Tempus ECG-AF offers valuable long-term risk stratification for atrial fibrillation, enabling earlier identification and follow-up, but its role is more for proactive management rather than immediate, life-saving intervention with causal insights.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF clearly outlines its value proposition with transparent CMS reimbursement information, including specific CPT codes and a Medicare rate, which simplifies the financial assessment for healthcare providers. Acumen HPI, however, requires direct contact for pricing and lacks publicly available evidence of cost savings, making its financial value less transparent and harder to ascertain upfront.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness, being HIPAA compliant and FDA cleared. Acumen HPI is deeply integrated within Edwards Lifesciences' established monitoring platforms, while Tempus ECG-AF is a flexible software solution designed to integrate with various existing ECG systems and EHRs. Each offers robust capabilities suitable for large healthcare organizations, albeit through different integration models.

Innovation

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Acumen HPI stands out with its real-time, continuous prediction of acute hypotensive events and its ability to provide dynamic, multi-faceted insights into underlying physiological causes (preload, afterload, contractility). While Tempus ECG-AF innovatively applies AI to standard ECGs for long-term risk prediction of AF, Acumen HPI's immediate, actionable, and complex physiological guidance in critical care represents a slightly higher degree of innovative application.

Support & Docs

Tie

Both companies appear to offer comprehensive support and documentation. Edwards Lifesciences provides 24/7 technical support and extensive clinical education resources for Acumen HPI. Tempus AI also offers a dedicated cardiology support team and a document library for Tempus ECG-AF. Without more detailed comparative information on the breadth and quality of these services, it is difficult to distinguish a clear winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform Tempus ECG-AF
Product Name Acumen Hypotension Prediction Index u0096 EV1000 Clinical Platform Tempus ECG-AF
Company Edwards Lifesciences Tempus AI, Inc.
Primary Function Predicts hypotensive events up to 15 minutes in advance, providing insights into hemodynamic instability and potential causes. Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Categories Cardiology AI, Surgical AI, Triage & ER/ICU AI Cardiology AI
Specialties Anesthesiology, Critical Care, Emergency Medicine Cardiology, Geriatrics, Internal Medicine
Prediction/Detection Horizon Up to 15 minutes in advance (hypotension) Within the next 12 months (new onset AF)
Target Patient Population Not specified Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery

Videos

Demos, reviews, and walkthroughs featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform and Tempus ECG-AF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Acumen HPI integrates with Edwards Lifesciences HemoSphere or EV1000 platforms via dedicated sensors, providing real-time hemodynamic insights at the bedside. Data transfer to the EHR would typically depend on the specific interface capabilities established between the monitoring platform and the facility's EHR system. Tempus ECG-AF is a software solution that analyzes standard 12-lead ECGs, fitting into existing diagnostic pathways. The AI-generated risk assessment is then interpreted by the physician and documented in the EHR to inform follow-up care.
Acumen HPI predicts hypotensive events up to 15 minutes in advance with demonstrated accuracy, including a reported sensitivity of 90% and specificity of 89% at 10 minutes before an event. Clinicians use the HPI score (0-100) and hemodynamic insights to proactively manage instability, though it's intended for adjunctive use and not to independently direct therapy. Tempus ECG-AF identifies patients 65 or older at increased risk of AF within 12 months, demonstrating a sensitivity of 31% and specificity of 92% in performance studies. Results should be interpreted in conjunction with other diagnostic information and clinical history, and not as the sole basis for diagnosis or treatment of AF.
Acumen HPI is highly beneficial in acute care settings like operating rooms, ICUs, and emergency departments for surgical and non-surgical patients at risk of rapid hemodynamic changes, such as during major non-cardiac surgery. Tempus ECG-AF is specifically designed for proactive screening in ambulatory settings for older adults (65+) without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, aiding in earlier identification for preventative strategies.
For Acumen HPI, clinicians need to learn to interpret the HPI score, Smart Alerts, and the Relationship View screen (preload, afterload, contractility insights) in real-time to guide interventions. Tempus ECG-AF requires clinicians to understand the AI's risk assessment (increased risk or no increased risk) in the context of a patient's overall clinical picture and the algorithm's specific criteria and limitations.
Multi-site rollout for Acumen HPI would involve deploying Edwards Lifesciences monitoring platforms and dedicated sensors across all units, requiring significant hardware and network infrastructure planning, along with training on the integrated system. Tempus ECG-AF, as a software solution, would focus on seamless system integration with existing ECG devices and EHRs across sites, along with standardized clinician training on interpreting the AI-generated risk assessments.
Time-to-value for Acumen HPI can be immediate in acute settings by guiding real-time interventions to reduce the duration and severity of hypotension. Ongoing support would typically be provided by Edwards Lifesciences' established clinical and technical support teams. Tempus ECG-AF's value accrues over time through earlier AF identification and improved patient outcomes, with vendor support generally covering software integration and clinical education.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform or Tempus ECG-AF

Backers

Who funded each tool's parent company.

Tempus ECG-AF

AI Tool Finder
AI-powered search. Results may not be comprehensive.